Sarah Pringle

Sarah Pringle is a reporter focusing on auctions in the retail and technology sectors. Prior to joining The Deal, Pringle reported on U.S. and Canadian equity markets at Bloomberg News in New York and MarketWatch in San Francisco.

Recent Articles By The Author

Abbott's Alere Deal Continues To Face Uncertainty

Abbott's Alere Deal Continues To Face Uncertainty

The medical device company has two pending acquisitions worth just under $40 billion combined.

Monsanto Rebuffs Bayer Again

Monsanto Rebuffs Bayer Again

The St. Louis-based target claims Bayer's revised $63.5 billion bid remains 'financially inadequate."

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

Analyst: Merck's Fundamentals Don't Warrant Current Valuation

BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.

Teva Makes Good Use of Rate Climate to Fund Allergan deal

Teva Makes Good Use of Rate Climate to Fund Allergan deal

The Israeli pharmaceutical company ought to achieve good terms as fixed-income investors flock to corporate bonds.

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.